Cellectis Gains FDA Orphan Drug Status for ALL Therapy
Company Announcements

Cellectis Gains FDA Orphan Drug Status for ALL Therapy

Cellectis SA (CLLS) has released an update.

Cellectis SA, a clinical-stage biotech company, has been granted Orphan Drug Designation by the FDA for its investigational drug CLLS52, intended for the treatment of B-cell acute lymphoblastic leukemia (ALL). This designation could accelerate the drug’s development and commercialization, and highlights Cellectis’ innovation in combining gene-edited CAR T-cells with a lymphodepleting regimen to enhance clinical effectiveness. The company specializes in gene-editing technologies and CAR-T immunotherapies, aiming to deliver off-the-shelf solutions for cancer patients.

For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCellectis S.A. Reports Q3 2024 Financial Results and Updates
TipRanks Auto-Generated NewsdeskCellectis SA Advances CAR T-cell Therapy for Solid Tumors
TheFlyCellectis price target lowered to $5 from $7 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App